

February 03, 2017**Scrip Code - 532330**

**To,
The Listing Department
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort.
Mumbai - 400 021**

Dear Sir / Madam,**Re: Outcome of the Board Meeting held on 03rd February 2017.**

This is to inform you that pursuant to Regulation 30 and 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, the Board of Directors of the Company at its Meeting held on today i.e. Friday, the 03rd February 2017, the following business was transacted:

- (a) The Un-audited Financial Results and Statement of Assets and Liabilities for the Third Quarter and Nine Months ended 31st December, 2016 along with Limited Review Report have been approved. (Enclosed)

The Meeting of the Board of Directors commenced at 4:30 pm and concluded at 5:45 pm

This is for your information and for the information of members of your exchange.

Kindly take the same on record and acknowledge the receipt.

**Thanking you,
Yours Faithfully
For BIOPAC INDIA CORPORATION LIMITED**



**Harish B. Doshi
Chairman
Encl: A/a**



BIOPAC INDIA CORPORATION LIMITED

Registered Office : Survey No. 38, Silvassa Khanvel Road, Dapada, Silvassa 396230 Dadra Nagar Haveli, India. CIN: L51900DN1987PLC000441

Statement of Standalone Unaudited Results for the Quarter and Nine Months Ended December 31, 2016

(PART- I)

(Rs. In Lacs)

PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR END
	31.12.2016 UNAUDITED	30.09.2016 UNAUDITED	31.12.2015 UNAUDITED	31.12.2016 UNAUDITED	31.12.2015 UNAUDITED	31.03.2016 AUDITED
1. Income from operations						
(a) Net sales/income from operations (Net of excise duty)	1,191.09	1,137.25	1,310.40	3,389.57	3,961.69	5,209.69
(b) Other operating income	-	-	-	-	-	-
Total income from operations (net)	1,191.09	1,137.25	1,310.40	3,389.57	3,961.69	5,209.69
2. Expenses						
(a) Cost of materials consumed	565.12	564.39	605.32	1,477.06	2,080.50	2,974.91
(b) Purchases of stock-in-trade	-	-	-	-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.19	(37.65)	70.21	33.79	(24.32)	(204.63)
(d) Employee benefits expense	189.87	195.39	189.13	593.62	553.96	744.95
(e) Depreciation and amortisation expense	138.77	138.48	136.29	413.02	408.01	544.05
(f) Other expenses	185.35	170.28	182.38	532.59	517.89	690.07
Total expenses	1,079.30	1,030.89	1,183.33	3,050.08	3,536.04	4,749.34
3. Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	111.78	106.37	127.07	339.49	425.65	460.35
4. Other income	0.07	0.12	0.11	0.31	0.58	2.99
5. Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	111.86	106.48	127.18	339.80	426.23	463.34
6. Finance costs	100.69	103.46	104.32	315.11	290.68	388.55
7. Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)	11.17	3.03	22.86	24.69	135.56	74.77
8. Exceptional items	-	-	-	-	-	-
9. Profit / (Loss) from ordinary activities before tax (7 + 8)	11.17	3.03	22.86	24.69	135.56	74.77
10. Tax expense	0.54	3.93	21.92	9.97	68.72	69.58
11. Net Profit / (Loss) from ordinary activities after tax (9 - 10)	10.63	(0.90)	0.94	14.72	66.84	5.19
12. Extraordinary items (net of tax expense)	-	-	-	-	-	-
13. Net Profit / (Loss) for the period (11 + 12)	10.63	(0.90)	0.94	14.72	66.84	5.19
14. Paid-up equity share capital (Share face value of 10/- each)	1,725.01	1,725.01	1,725.01	1,725.01	1,725.01	1,725.01
15. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	288.08
16. EARNING PER SHARE (EPS) (before extraordinary items) (of ` 10/- each) (not annualised):						
(a) Basic	0.06	(0.01)	0.01	0.09	0.39	0.03
(b) Diluted	0.06	(0.01)	0.01	0.09	0.39	0.03

NOTES:

- The above results were reviewed by the Audit Committee and approved at the Meeting of the Board of Directors held on February 03, 2017. The statutory Auditors have carried out a limited review of the unaudited financial results of the company for the quarter ended December 31, 2016.
- The figures for the previous period have been regrouped where necessary to conform to current period's classification.

For Biopac India Corporation Limited



Harish Doshi

Harish Doshi
Chairman

Date: 03.02.2017
Place: Mumbai



SHAH, SHAH & SHAH (Regd.)
Chartered Accountants

Review Report to
BSE Limited
P. J. Towers, Fort,
Bombay Samachar Marg,
Mumbai – 400023

We have reviewed the accompanying statement of unaudited financial results of **Blopac India Corporation Limited** for the period ended 31st December, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SHAH, SHAH & SHAH
CHARTERED ACCOUNTANTS

(Mehul C. Shah)

Partner

Membership No. 49361

FRN. : 116457W

Mumbai : January 31, 2017

